A Sister’s Perspective – Emma Smith (Trustee)

We had all plunged into a big black hole of despair in the days which followed my sister Helen’s metastatic breast cancer (MBC) diagnosis.  Two and a half years on

Drugs drugs everywhere, can you access ones that work? Kirstin Spencer

Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge

METUPUK at the UK Interdisciplinary Breast Cancer Symposium

METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a

PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer

METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline

NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib

METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with